Merry Christmas Everyone!
This year, instead of Christmas cards, I’ve donated to the wonderful ‘Children with Cancer in Malawi’ charity justgiving.com/charity/childr…. You could do the same if you’re interested?!
Wishing you all a happy and healthy 2026!

We would like to extend a heartfelt thank you to everyone who contributed to this achievement, and to our members, collaborators, funders and supporters who have helped make this possible.

UK children and young people’s cancer experts come together for CCLG Annual Conference CCLG: The Children & Young People’s Cancer Association hosts its Annual Conference next week (March 24-25), bringing together experts from across the childhood, teenage and young adult cancer communit...

We can't wait to welcome delegates to our biggest-ever annual conference next week in Birmingham!

We've got an ambitious programme of talks, workshops and more, packed with valuable insights on treatment, care and research. See you there! 👋🤩

bit.ly/4hs4bPR

#CCLG2025

CCLG and TYAC come together to unite children’s and young people’s cancer community Children’s Cancer and Leukaemia Group (CCLG) and Teenagers and Young Adults with Cancer (TYAC) have merged their memberships to form a new professional association which will bring together healthcare...

Why have CCLG and TYAC merged their memberships to form a new professional association?

To foster greater collaboration, enhance access to resources, and build a stronger community dedicated to advancing treatment, care and support for #CYP with cancer 💛

www.cclg.org.uk/news-updates...

Oh my days....70 years in the making!

Exploring children's and young people's cancers: Clinical research Join us for the second webinar in our series where we will be exploring how we can learn more from clinical trials.

I’m pleased to be speaking at the @cancerresearchuk.org upcoming children’s & young people’s cancers webinar on exploring further discoveries from clinical research. Join me on 12 February from 3–4:30 pm (GMT): bit.ly/3BsXMF0 #ExploringCYPCancers @nucancer.bsky.social

Catch me getting mean at the Carlton Club Manchester on 4th February alongside brilliant comedy minds @martinmerry.bsky.social @erinbeeston.bsky.social @katedoingscience.bsky.social @maxmatics.bsky.social
Photo credit @drstevex.bsky.social

PhD studentship in paediatric brain tumour research – Integrative multi-omic analyses of childhood medulloblastoma for improved personalised therapies at Newcastle University on FindAPhD.com PhD Project - PhD studentship in paediatric brain tumour research – Integrative multi-omic analyses of childhood medulloblastoma for improved personalised therapies at Newcastle University, list...

PhD post available: Are you interested in using contemporary ‘omics approaches to uncover clinically-relevant biology in medulloblastoma, the most common malignant brain tumour in children? Join our Childhood Brain Tumour Research team @nucancer.bsky.social
See www.findaphd.com/phds/project...

PhD studentship in paediatric brain tumour research – Integrative multi-omic analyses of childhood medulloblastoma for improved personalised therapies at Newcastle University on FindAPhD.com PhD Project - PhD studentship in paediatric brain tumour research – Integrative multi-omic analyses of childhood medulloblastoma for improved personalised therapies at Newcastle University, list...

PhD post available: Are you interested in using contemporary ‘omics approaches to uncover clinically-relevant biology in medulloblastoma, the most common malignant brain tumour in children? Join our Childhood Brain Tumour Research team @nucancer.bsky.social
See www.findaphd.com/phds/project...

In this Review, Tao et al. discuss the origins and heterogeneity of pediatric medulloblastoma, through the molecular lens of cerebellar development, for the advancement of disease modeling, treatment and outcomes. #OpenAccess

Learn more here:
➡️ tinyurl.com/gd351936

ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip - Nature Genetics Analysis of medulloblastomas in humans and mice shows that the functional consequences of ZIC1 mutations are exquisitely dependent on the cells of origin that give rise to different subgroups of medul...

ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip
www.nature.com/articles/s41...

Rare germline structural variants increase risk for pediatric solid tumors Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using ge...

Interesting paper now published in Science👇🏻

www.science.org/doi/10.1126/...

Blood Cancer UK | Blood cancer researcher recognised in King’s New Years Honours The King’s New Years Honours list has been announced with Blood Cancer UK's trustee awarded an OBE for services to children.

Delighted to see that Christine Harrison has been awarded an OBE in the NY Honours List. A wonderful recognition for excellent childhod leukaemia research. Congratulations!

#leukaemia #newcastleuniversity #lrcg #research #cancer #leukemia @nucancer.bsky.social

bloodcancer.org.uk/news/blood-c...

Happy Holidays！💐

Credit to: Dario Brunetti

Promotional image for Newcastle University highlighting its ranking in the top 60 of the QS World University Rankings for Sustainability 2025. The photo features a lush campus courtyard with traditional red brick buildings and walking paths.

🎉 We're celebrating being listed one of the world's top 60 universities for sustainability by QS.

We're also joint 3rd in the world for health and wellbeing impact - recognising our mission to help people around the globe live longer and healthier lives.

#WeAreNCL #QSWUR

👍

Please add me! Thanks!

We are one of just 7 UK cancer centres that are contributing to the CRUK Black Leaders in Cancer PhD Scholarship Programme. We have 10 exciting projects on offer to eligible candidates of Black heritage backgrounds. Read more about the scheme and what we have on offer www.ncl.ac.uk/cancer/train...

👍

Please add me! Thanks!

Please add me. Thanks.

Please add me. Cheers.

Did you know that scientists in our @cruk-si.bsky.social Drug Discovery Unit were the brains behind Rucaparib (PARP inhibitor) and Erdafitinib (FGFR inhibitor, both now clinically approved cancer medicines. Read more about our ground breaking drug discovery science here www.ncl.ac.uk/cancer/our-r...